ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.

Nihal Narsipur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.